OSR HOLDINGS INC (OSRH)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.28+136.05%
Close 2026-08-31 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Improve financial performance and reduce losses: Net loss ~$1.0M in 2026-Q2 vs <$3M target.
OSR Holdings is expanding through M&A deals, including agreements with Vaximm AG and BCM Europe AG. The company aims to improve financial performance despite recent losses of about $3.5 million in 2026-Q1. Legal and regulatory challenges are being addressed, which could stabilize operations.
OSR Holdings is loss-making with a negative free cash flow yield of -0.51 and no earnings expected in 2026. The stock has fallen 57.8% from its high and faces ongoing legal and regulatory risks, including Nasdaq delisting notices and litigation. Revenue estimates for 2027 are low at $71.65 million, showing limited growth prospects.
The market prices in a weak outlook with implied negative growth of -29.7% over 3 years and a share price about 65% below consensus estimates. Our fair value at $0.89 reflects the company's distressed status, while the market expects continued losses and regulatory challenges.
Breaks if: Net loss exceeds $3.5 million in any quarter after 2026-Q1
Breaks if: New major litigation or regulatory delisting notices occur after 2026-Q2
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment with a focus on biopharma assets. The current thesis state reflects mixed management execution and high risk, making it a cautious watch.
The market appears to price in a low level of fragility, with OSRH being considered cheap compared to its peers. However, there is a divergence in valuation, suggesting that expectations may not fully account for the company's ongoing losses and high risk.
Fundamentals are likely to remain volatile due to ongoing losses and mixed management priorities. Recent financial performance has shown some recovery, but the company still faces significant capital needs and a high probability of missing earnings expectations.
The thesis hinges on the performance of sector bellwethers and the execution of management's strategic priorities. Any unfavorable trends in the broader healthcare sector or further legal/regulatory challenges could negatively impact OSRH.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Fails to complete any material M&A deal by end of 2026
Over the next 1 to 3 years, OSRH's performance will depend on its ability to navigate high risks and capitalize on sector momentum. Not investment advice.